Profiling Spike Protein Antibody Response Post COVID-19 Booster
The clinical trial titled 'Profiling Spike Protein Antibody Response Post COVID-19 Booster' was sponsored by the David Grant U.S. Air Force Medical Center. The study aimed to quantify the mean IgG antibody levels in vaccinated individuals following a COVID-19 booster. However, the trial was withdrawn due to the lack of IRB approval and no participant enrollment. This withdrawal indicates potential challenges in conducting clinical research within military or federally regulated environments, which may affect future studies targeting similar populations. The market for COVID-19 vaccines and boosters remains competitive, with ongoing interest in understanding long-term immunity and antibody responses, particularly in military and high-risk populations. Companies focusing on antibody testing and vaccine efficacy may find this data relevant for product development and positioning.
Indication: COVID-19 Booster
Modality: monoclonal antibody
Target: SARS-CoV-2 spike protein IgG antibodies
Sponsor: David Grant U.S. Air Force Medical Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: SARS-CoV-2 spike protein IgG antibodies
View original source fields
Condition raw: COVID-19 Booster, Spike Protein IgG Antibody
Condition normalized: COVID-19 Booster, Spike Protein IgG Antibody
Modality raw: monoclonal antibody
Modality normalized: monoclonal antibody
Target raw: SARS-CoV-2 spike protein IgG antibodies
Target normalized: SARS-CoV-2 spike protein IgG antibodies